Respiratory Trials·org

Topic

Haematology in critical care

Transfusion, anticoagulation, and thrombocytopenia in the ICU.

What the evidence shows

Transfuse at 7 g/dL. A restrictive threshold was at least as effective as a liberal one in critically ill patients, and possibly better in the young and less acutely ill (TRICC). The authors' own exception — myocardial infarction and unstable angina — has kept researchers busy for twenty-five years and remains unresolved.

In acute chest syndrome, therapeutic-dose anticoagulation shortened the episode from 6.1 to 4.8 days and nearly halved opioid requirement, without major bleeding in either arm (TASC). With 101 patients, a bleeding risk cannot be excluded.

Anticoagulation in acute chest syndrome

Trial Year Therapy Effect Finding
TASC 2025 Therapeutic-dose anticoagulation Therapeutic-dose anticoagulation shortened acute chest syndrome and nearly halved opioid use without causing bleeding

Transfusion threshold in critical illness

Trial Year Therapy Effect Finding
TRICC 1999 Restrictive transfusion strategy Transfusing at 7 rather than 10 g/dL was at least as good, and possibly better

Key references

Guidelines, standards and reviews for this topic.